New ambr® Bioreactor Systems Enhanced with Software for Design of Experiments (DoE)

sarto-stedim-bio logo

Enables Robust, Flexible Bioprocess Development in Single-use Bioreactors

Goettingen, Germany and Cambridge, UK, February 25, 2015 / B3C newswire / - Sartorius Stedim Biotech (SSB) today announced the 2015 version of the ambr® systems (ambr® 15 and ambr® 250) will be supplied with integrated BioPAT® MODDE Software for Design of Experiments (DoE), powered by Umetrics. This will allow bioprocess scientists to easily implement DoE into their work flow for simpler process optimisation and scale-up to larger single-use BIOSTAT® pilot and manufacturing scale bioreactors, making bioprocess development faster and more cost-effective.

The integrated DoE software will enable scientists to quickly establish a Design Space where relevant bioprocessing conditions are varied simultaneously. Users can rapidly configure DoE experiments via work packets that are exported from the software to the ambr system; configuring each micro bioreactor with its own DoE defined bioprocessing parameters. The data generated from ambr, including offline analytics, is analysed within the software to identify critical process parameters, optimise bioprocessing conditions and define a robust design space for implementation in larger single-use BIOSTAT pilot and manufacturing scale bioreactors.

This extended DoE functionality is also available to existing ambr users who can assess the utility of the BioPAT MODDE software via a free 60 day trial, with the option of purchasing the full version if they want to continue to run DoE programmes.

Dr Barney Zoro, ambr15 Product Manager at SSB commented: "To facilitate greater implementation of DoE across the industry we have combined the power of ambr with the BioPAT MODDE software. These synergistic technologies are ideally suited for media optimisation and process parameter screening applications. Additionally, the software can be used for Monte Carlo Simulations as part of a Quality by Design (QbD) programme to identify the desired operating region for manufacturing scale processes, to make scale-up quicker and simpler.”

Mario Becker, Director of Marketing, PAT and Automation at SSB, continued: “Our major goal is to ensure that bioprocess scientists can develop their processes as quickly as possible. Providing a consistent, scalable platform for DoE studies and data analysis which is seamlessly integrated with the full range of ambr and BIOSTAT systems, will help scientists develop robust and flexible manufacturing processes based on single-use bioreactor technology. Ultimately, implementing this approach and extending it with the BioPAT SIMCA MVDA toolkit will contribute to biotech and pharma firms reducing risk in bioprocess development and achieving more rapid, cost-effective production of their biologics and vaccines.”

Image Files:

ambr15 application

Caption: ambr® 15 system, now with integrated DoE software, the leading micro bioreactor system for cell line development and early process optimisation
Link to the high resolution picture:

ambr 250 product 1

Caption: ambr® 250 system, now with integrated DoE software, the high throughput scale-down model for process development
Link to the high resolution picture:

More information:

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

TAP Biosystems, part of the Sartorius Stedim Biotech Group, is a leading global provider of automated cell culture and fermentation systems for life science research, development and production. TAP's systems are in use worldwide at pharmaceutical, biotechnology and academic laboratories, supporting bioprocess development and GMP manufacture of biologics and cell therapies, as well as discovery and stem cell research programmes.


Dominic Grone
Senior Manager Corporate Communications, Sartorius Stedim Biotech
Tel: +49 (0)551.3083324
This email address is being protected from spambots. You need JavaScript enabled to view it.

Michaela McAdam,
Marketing Communications Manager, Sartorius Stedim Biotech | TAP Biosystems
Tel: +44 (0) 1763 227200
This email address is being protected from spambots. You need JavaScript enabled to view it.


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.